61MA Stock Chart & Stats
€50.30
€0.90(1.70%)
At close: 4:00 PM EST
€50.30
€0.90(1.70%)
Day’s Range― - ―
52-Week Range€41.20 - €59.60
Previous CloseN/A
Volume0.00
Average Volume (3M)4.00
Market Cap
€748.77M
Enterprise Value€8.03K
Total Cash (Recent Filing)€286.30M
Total Debt (Recent Filing)€457.60M
Price to Earnings (P/E)34.2
Beta0.35
Next Earnings
Oct 23, 2026EPS Estimate
0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)16.04
Shares Outstanding15,080,753
10 Day Avg. Volume0
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio7.70
Price to Book (P/B)5.67
Price to Sales (P/S)3.90
P/FCF Ratio29.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.04
Revenue Forecast (FY)€212.07M
Bulls Say, Bears Say
Bulls Say
Revenue Scale & GrowthSustained multi-year revenue scaling more than doubles the company's size since 2021, enabling durable advantages: broader commercial reach, better procurement leverage, and capacity to fund R&D and add-on acquisitions. This higher recurring revenue base underpins longer-term operating profit resilience.
Active Buy-and-build ModelMedCap's focused roll-up strategy in medical devices and diagnostics creates structural value: platform consolidation, cross-selling, and operational uplift across niche subsidiaries. Active ownership coupled with targeted add-ons supports durable revenue diversification and repeatable value creation.
Strong Free Cash Flow GenerationConsistent and growing FCF near net income provides lasting financial flexibility to fund acquisitions, capex and operational improvements without heavy equity issuance. Robust cash generation supports reinvestment in portfolio businesses and cushions execution risk over the medium term.
Bears Say
Inconsistent Cash ConversionSub‑1.0x operating cash flow coverage signals persistent working-capital timing risk and uneven conversion of profits to cash. Over months this can constrain internal funding for add‑ons or capex, raise reliance on external financing, and increase sensitivity to operational disruptions.
Rising Total DebtThe increase in absolute debt levels reduces financial flexibility and raises refinancing and interest exposure ahead. If cash conversion weakens or acquisition pace slows, elevated debt could pressure liquidity or force tighter capital allocation, constraining long‑term strategic optionality.
Gross Margin VolatilityLarge swings in gross margin suggest mix shifts, reclassifications, or cost variability that undermine predictability of unit economics. Persistent margin volatility complicates forecasting, weakens confidence in sustainable profitability, and raises execution risk for margin-improvement strategies.
MedCap AB News
61MA FAQ
What was MedCap AB’s price range in the past 12 months?
MedCap AB lowest stock price was €41.20 and its highest was €59.60 in the past 12 months.
What is MedCap AB’s market cap?
MedCap AB’s market cap is €748.77M.
When is MedCap AB’s upcoming earnings report date?
MedCap AB’s upcoming earnings report date is Oct 23, 2026 which is in 85 days.
How were MedCap AB’s earnings last quarter?
MedCap AB released its earnings results on Jul 21, 2026. The company reported €0.477 earnings per share for the quarter, beating the consensus estimate of €0.429 by €0.049.
Is MedCap AB overvalued?
According to Wall Street analysts MedCap AB’s price is currently Overvalued.
Does MedCap AB pay dividends?
MedCap AB does not currently pay dividends.
What is MedCap AB’s EPS estimate?
MedCap AB’s EPS estimate is 0.4.
How many shares outstanding does MedCap AB have?
MedCap AB has 15,080,753 shares outstanding.
What happened to MedCap AB’s price movement after its last earnings report?
MedCap AB reported an EPS of €0.477 in its last earnings report, beating expectations of €0.429. Following the earnings report the stock price went up 4.461%.
Which hedge fund is a major shareholder of MedCap AB?
Currently, no hedge funds are holding shares in DE:61MA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedCap AB
MedCap AB (publ) operates as a private equity firm, employing a diverse array of investment strategies including secondary direct deals, later-stage funding, industry consolidation, growth capital provision, engagement with middle-market and mature businesses, turnarounds, and outright buyouts. The company primarily directs its capital towards businesses within the healthcare sector, focusing on medical equipment and services, biotechnology, life sciences, and pharmaceuticals. It actively seeks unlisted, small to mid-sized companies located predominantly across Northern Europe. Equity investments typically fall within the SEK 25 million to SEK 150 million range (approximately $2.75 million to $16.51 million). Target companies generally exhibit an enterprise value and annual sales revenue between SEK 50 million and SEK 200 million ($5.90 million to $23.06 million), alongside an EBITDA of SEK 1 million to SEK 50 million ($0.11 million to $5.50 million). MedCap aims to acquire ownership stakes of 20% to 50% in its portfolio entities, financing these through its own capital, loans, and direct balance sheet investments. Established in 2001, the firm maintains its headquarters in Stockholm, Sweden.